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Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (alloHCT) remains a
major therapeutic challenge. We studied outcomes of 1788 AML patients relapsing after alloHCT (1990 to
2010) during ﬁrst or second complete remission (CR) to identify factors associated with longer postrelapse
survival. Median time to post-HCT relapse was 7 months (range, 1 to 177). At relapse, 1231 patients (69%)
received intensive therapy, including chemotherapy alone (n ¼ 660), donor lymphocyte infusion (DLI) 
chemotherapy (n ¼ 202), or second alloHCT  chemotherapy  DLI (n ¼ 369), with subsequent CR rates of
29%. Median follow-up after relapse was 39 months (range, <1 to 193). Survival for all patients was 23% at 1
year after relapse; however, 3-year overall survival correlated with time from HCT to relapse (4% for relapse
during the 1- to 6-month period, 12% during the 6-month to 2-year period, 26% during the 2- to 3-year period,
and 38% for 3 years). In multivariable analysis, lower mortality was signiﬁcantly associated with longer time
from alloHCT to relapse (relative risk, .55 for 6 months to 2 years; relative risk, .39 for 2 to 3 years; and
relative risk, .28 for 3 years; P < .0001) and a ﬁrst HCT using reduced-intensity conditioning (relative risk,
.77; 95% conﬁdence interval [CI], .66 to .88; P ¼ .0002). In contrast, inferior survival was associated with age
>40 years (relative risk, 1.42; 95% CI, 1.24 to 1.64; P < .0001), active graft-versus-host disease at relapse
(relative risk, 1.25; 95% CI, 1.13 to 1.39; P < .0001), adverse cytogenetics (relative risk, 1.37; 95% CI, 1.09 to 1.71;
P ¼ .0062), mismatched unrelated donor (relative risk, 1.61; 95% CI, 1.22 to 2.13; P ¼ .0008), and use of cord
blood for ﬁrst HCT (relative risk, 1.23; 95% CI, 1.06 to 1.42; P ¼ .0078). AML relapse after alloHCT predicted
poor survival; however, patients who relapsed 6 months after their initial alloHCT had better survival and
may beneﬁt from intensive therapy, such as second alloHCT  DLI.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (alloHCT) is
a potentially curative treatment option for patients with
acute myeloid leukemia (AML); however, relapse accounts
for approximately 40% of alloHCT treatment failures. Among
relapsed patients, the 2-year postrelapse survival rate is re-
ported at less than 20% [1-7]. Unfortunately, sustainable re-
missions are rare in patients with post-transplantation AMLedgments on page 458.
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ty for Blood and Marrow Transplantation.relapse, especially for those relapsing soon after alloHCT
[8,9]. Commonly used treatment options for relapsed pa-
tients include intensive chemotherapy with or without
donor lymphocyte infusion (DLI), second alloHCT, with-
drawal of immunosuppression, or supportive care [4,7,8,10-
13]. Treatment decisions for management of relapsed AML
could be improved by identifying prognostic factors associ-
ated with postrelapse survival and developing a risk strati-
ﬁcation model.
A recent study by the European Blood and Marrow
Transplantation group identiﬁed several prognostic factors
associated with improved survival among AML patients who








No. of patients 1788 413
Year of HCT
1990-2000 745 (42) 203 (49)
2001-2010 1043 (59) 210 (51)
HCT during
CR1 1249 (70) 312 (76)
CR2 539 (30) 101 (24)
Age
Median (range) 32 (<1-76) 30 (1-75)
0-18 yr 613 (34) 136 (33)
19-40 yr 439 (25) 138 (33)
41-76 yr 736 (41) 139 (34)
AML type
De novo 1450 (81) 348 (84)
Secondary 276 (15) 47 (11)
Missing 62 (3) 18 (4)
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marrow tumor burden at relapse, and absence of acute graft-
versus-host disease (GVHD). Longer survival was seen pri-
marily among patients who achieved complete remission
(CR) with chemotherapy followed by either DLI or a second
alloHCT [1]. These ﬁndings are consistent with other single-
institution reports of alloHCT outcomes among patients
treated for relapsed AML. These reports suggested that
intensive therapy resulted in better survival thanwithdrawal
of immunosuppression alone [5,7,11], independent of donor
source or intensity of initial conditioning [7]; however, a
detailed analysis of prognostic factors associated with sur-
vival was limited by the relatively small sample sizes of these
previous reports. We, therefore, used the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR)
database to compare clinical outcomes and factors associated
with survival among a large cohort of AML patients whose
leukemia relapsed after alloHCT.Cytogenetics scoring
Favorable 138 (8) 45 (11)
Intermediate/normal 805 (45) 190 (46)
Unfavorable 334 (19) 52 (13)
Missing 511 (29) 126 (31)
Myeloablative 1374 (77) 337 (82)
RIC/NMA 414 (23) 76 (18)
Graft type
Bone marrow 935 (52) 240 (58)
Peripheral blood 621 (35) 138 (33)
Cord blood 232 (13) 35 (8)
Donor type
HLA-identical sibling 936 (52) 245 (59)
URD well matched 317 (18) 69 (17)
URD partially matched 134 (7) 35 (8)
URD mismatched 56 (3) 7 (2)
URD unknown 113 (6) 22 (5)METHODS
Data Source
We used the CIBMTR observational registry to compare clinical out-
comes and factors associated with survival among AML patients whose
leukemia relapsed after alloHCT between 1990 and 2010. The CIBMTR is a
research organization combined with the National Marrow Donor Program
that collects information from over 500 transplantation centers worldwide
that prospectively report detailed information on consecutive trans-
plantations. To ensure data quality, a computerized system and scheduled
data audits independently check all collected data based on speciﬁc disease
forms provided by participating transplantation centers. Privacy protections
for patients participating in observational studies conducted by the CIBMTR
are in compliance with all applicable federal regulations. Additionally, the
CIBMTR ensures protected health information for all participants under the
Health Insurance Portability and Accountability Act Privacy Rule.Cord blood 232 (13) 35 (8)
GVHD prophylaxis
ATG/alemtuzumab 406 (23) 80 (19)
Ex vivo T cell depletion 48 (3) 12 (3)
CSA/tac  other 1334 (75) 321 (78)
Time from HCT to relapse
Median (range) 7 (1-177) 14 (1-177)
<6 mo 774 (43) 88 (21)
6 mo-2 yr 702 (39) 191 (46)
2-3 yr 138 (8) 52 (13)
3 yr 174 (10) 82 (20)
AML relapse site
Extramedullary only 80 (4) 25 (6)
Bone marrow  other sites 1046 (59) 200 (48)
Not reported/missing 662 (37) 188 (44)
Active GVHD before relapse
Yes 727 (41) 170 (41)
No 1028 (57) 234 (57)
Missing 33 (2) 9 (2)
Treatment for relapse
Second HCT  chemo  DLI 369 (21) 182 (44)
DLI  chemo 202 (11) 57 (14)Patient Selection and Deﬁnitions
Adult and pediatric patients with AML relapsing after alloHCT were
included in the study if they were in ﬁrst or second CR when they received
myeloablative or RIC alloHCT. Patients with de novo or secondary AML and
patients receiving related donor (RD), unrelated donor (URD), or umbilical
cord blood (UCB) donor grafts were included. Patients whose AML relapsed
within the ﬁrst 30 days of transplantation (n ¼ 64) or whose relapse date or
conditioning regimens were unavailable for analysis (n ¼ 106) were
excluded.
CR was deﬁned as <5% bone marrow blasts with no morphological ev-
idence of leukemia in the marrow or peripheral blood. Secondary AML was
deﬁned as leukemia arising from underlying myelodysplastic syndrome or
treatment-related AML due to previous chemotherapy or radiation. The
Southwest Oncology Group cytogenetic classiﬁcation was used for cytoge-
netic risk stratiﬁcation as previously reported [14]. Intensive therapy was
deﬁned as induction-type cytoreductive chemotherapy with or without DLI
and/or second allograft. HLA typing for URD recipients was classiﬁed using
published CIBMTR criteria [15]. Intensity of conditioning regimens was
classiﬁed according to established CIBMTR deﬁnitions [16,17].Chemo only 660 (37) 87 (21)
Supportive care/no therapy 357 (20) 35 (8)
Missing 200 (11) 52 (13)
Response to therapy
CR 271 (15) 165 (40)
No response 704 (39) 121 (29)
Missing 813 (45) 127 (31)
Surviving at last follow-up 229 (13) 173 (42)
Median follow-up after relapse, mo 39 (<1-193) 59 (12-193)
ATG indicates antithymocyte globulin; CSA, cyclosporine; tac, tacrolimus.Study Endpoints and Statistical Analysis
The primary study endpoint was overall survival (OS) of AML patients
relapsing after alloHCT. OS was deﬁned as the time from relapse to death or
last follow-up for surviving patients. Secondary endpoints included clinical
and disease prognostic factors of OS after post-transplantation relapse.
Long-term survival was deﬁned as survival 1 year after alloHCT relapse.
The Kaplan-Meier method was used to estimate OS probability [18]. Cox
proportional hazards regression model was used to identify factors pre-
dictive of survival. The assumption of proportional hazards for each factor
was tested by adding a time-dependent covariate. When the test indicated
differential effects over time (nonproportional hazards), models were con-
structed breaking the post-transplantation time course into 2 periods, using
the maximized partial likelihood method to ﬁnd the most appropriate
breakpoint. A stepwise model selection approach was used to identify all
signiﬁcant risk factors predictive of survival. All statistical analysis was
performed with SAS software (SAS Institute, Cary, NC, Version 9.2).RESULTS
Patient Characteristics
We identiﬁed 1788 patients with AML relapsing after
alloHCT from 286 CIBMTR centers in 43 countries. Of these,
413 patients survived1 year after relapse (Table 1). Median
Table 2






DLI  Second HCT 267 87
DLI þ chemotherapy
Yes 216 (81) 75 (86)
No 51 (19) 12 (14)
DLI* þ second HCT
þ Second HCT 65 (24) 30 (34)
No second HCT 202 (76) 57 (66)
Type of donor
HLA-identical sibling 162 (61) 59 (68)
Unrelated 102 (38) 26 (30)
Missing 3 (1) 2 (2)
Donor gender
Male 144 (54) 46 (53)
Female 105 (39) 38 (44)
Missing 18 (7) 3 (3)
Time from relapse to DLI
Median (range) 2 (<1-12) 2 (<1-12)
6 mo 226 (85) 70 (80)
>6 mo 11 (4) 5 (6)
Missing 25 (9) 9 (10)
Second HCT 369 182
Conditioning
MA 181 (49) 99 (54)
RIC/NMA 110 (30) 57 (31)
Missing 78 (21) 26 (14)
Donor type of second HCT
Related 197 (53) 94 (52)
Unrelated 127 (34) 70 (38)
Cord blood 20 (5) 9 (5)
Missing 25 (7) 9 (5)
Donor gender
Male 168 (46) 78 (43)
Female 126 (34) 67 (37)
Missing 75 (20) 37 (20)
Same donor as ﬁrst HCT
No 81 (22) 49 (27)
Yes 166 (45) 73 (40)
Missing 122 (33) 60 (33)
Time from relapse to second HCT
Median (range) 3 (<1-50) 3 (<1-50)
6 mo 299 (81) 135 (74)
>6 mo 52 (14) 40 (22)
Missing 18 (5) 7 (4)
MA indicates myeloablative.
* Reﬂects DLI with or without chemotherapy.
N. Bejanyan et al. / Biol Blood Marrow Transplant 21 (2015) 454e459456time from transplantation to relapse was 7 months (range, 1
to 177 months) and median follow-up of survivors after
post-transplantation relapse was 39 months (range, <1 to
193 months). Seventy percent of the patients underwent
alloHCT in CR1. Median age of patients was 32 years (range,
<1 to 76); 37% of patients were children (0 to 18 years old)Figure 1. (A) Adjusted OS by time from HCT to reand 39% were >40 years old. Fifteen percent of patients had
secondary AML and 19% had unfavorable cytogenetics. A
myeloablative conditioning regimen was used on over three
quarters of cases and 52% of patients received a bone
marrow graft. Donor types included HLA-identical RD (52%),
well-matched URD (25%), UCB (13%), and mismatched URD
(3%). Relapse within 6 months of transplantation occurred in
43% of patients, and isolated extramedullary relapse was
rare (4%). AML relapse beyond 2 years of alloHCT occurred in
only 18% of cases, and active GVHD before relapse was
present in 41% of patients. The majority (n ¼ 1231, 69% of
total) of patients received treatment for relapse, which
included chemotherapy alone (37%), second HCT with or
without chemotherapy and/or DLI (21%), or DLI with or
without chemotherapy (11%). However, only 15% of all pa-
tients achieved a subsequent CR. Although second HCTs
were rarely administered to those relapsing within 6
months, we found no association between use of intensive
therapy and the time from HCT to relapse or the condi-
tioning intensity of the ﬁrst HCT.
Median time from HCT to relapse was 14 months for long-
term survivors (>1 year after relapse). Survivors living longer
often received active treatment for relapse (79%), most
frequently a second HCT (44%), and they commonly achieved
subsequent CR (40%).Management of Post-transplantation Relapse
A total of 267 patients received DLI for AML relapse, and
DLI plus chemotherapy was used in 81% of them (Table 2).
DLI was followed by second HCT in 24% of patients treated
with DLI. Median time from relapse to DLI was 2 months
(range, <1 to 12 months), with 85% of patients receiving DLI
within 6 months of leukemia relapse. Among all patients
receiving DLI, 87 (32.6%) survived more than 1 year after
leukemia relapse. The source of DLI was an HLA-identical
sibling donor for 61% of patients. Patients who received DLI
and survived beyond 1 year often received a subsequent
second HCT (34%).
A second HCT was performed on 369 patients, of whom
182 (49.3%) survived more than 1 year after relapse. The
second HCT conditioning regimens were myeloablative for
49%, RIC/or nonmyeloablative (NMA) for 30%, and unknown
for the rest of the patients. RD second HCT was performed in
about one half, URD in one third, UCB in 5% of the patients,
and second HCT donor source was unknown for the rest of
the cases. A different donor for the second HCTwas chosen in
45% of patients but data on the donor were unavailable for
one third of patients. Median time from post-transplantation
leukemia relapse to the second HCT was 3 months (range,<1lapse. (B) Adjusted overall survival by age.
Table 3

















<6 mo 90 12 (13) <.001 110 35 (32) <.001
6 mo-2 yr 81 28 (35) 167 92 (55)
2-3 yr 14 7 (50) 37 23 (62)








* P value reﬂects the time from HCT to relapse.
y Median survival of all patients receiving DLI.
z Median survival of all patients receiving second HCT.
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within 6 months.
Among patients with evaluable status for response to
therapy (n ¼ 846), subsequent CR was achieved in 29% of
patients. DLI with or without chemotherapy (n ¼ 139)
resulted in CR for 37% of cases, second HCT with or without
chemotherapy and/or DLI (n ¼ 264) resulted in CR for 44%,
and chemotherapy alone (n ¼ 443) induced CR in only 16%.
Only rare remissions (6%) were observed among patients
managed supportively.Survival after Post-transplantation Relapse
Median follow-up was 39 months after relapse (<1 to 193
months). Only 13% of all patients remained alive at the time of
study analysis. Survival at 1 year after post-transplantationTable 4
Factors Inﬂuencing Survival of AML Patients Relapsing after alloHCT
Variable n Univariate
RR (95% CI)
Time from HCT to relapse
<6 mo 774 1.00
6 mo-2 yr 702 .60 (.53-.66)
2-3 yr 138 .40 (.33-.50)
3 yr 174 .30 (.24-.37)
Year of HCT
1990-2000 745 1.00
2001-2010 1043 1.19 (1.08-1.32)
Age
18 yr 656 1.00
19-40 yr 433 .86 (.75-.98)
41 yr 699 1.27 (1.13-1.42)
Gender
Male 988 1.00
Female 800 .98 (.88-1.08)
Cytogenetics
Favorable 138 1.00
Intermediate/normal 805 1.27 (1.04-1.56)
Unfavorable 334 1.64 (1.32-2.04)
Unknown 511 1.22 (.99-1.51)
Conditioning
MA 1374 1.00
RIC/NMA 414 1.18 (1.05-1.33)
Donor type
RD/URD-matched 1387 1.00
URD-mismatched 56 1.65 (1.25-2.17)
URD-unknown 113 1.10 (.90-1.35)
Cord blood 232 1.38 (1.19-1.60)
Active GVHD at relapse
No 1028 1.00
Yes 727 1.10 (.99-1.21)
Unknown 33 1.01 (.70-1.47)
RR indicates relative risk.relapse was 23%; however, survival probability at 3 years
was only 4% for patients relapsingwithin 6months of alloHCT,
12% for those relapsing from 6 months to 2 years, 26% for 2 to
3 years, and 38% for 3þ years (Figure 1A). Adjusted proba-
bilities of survival at 3 years were 13% for patients younger
than 18 years, 17% for those 19 to 40 years old, and 8% for
patients older than 41 years (Figure 1B). Median survival was
7 months (range, 1 to 177 months) among patients receiving
DLI and 12 months (1 to 150 months) among those receiving
second HCT. Cell-based therapy (DLI or second HCT) resulted
into signiﬁcantly better 1 year post-relapse survival among
patients relapsing 6 months and later after HCT (Table 3). In
multivariable analysis, a longer time from HCT to relapse (P <
.0001) and use of a RIC/NMA conditioning regimen (hazard
ratio [HR], .77; P ¼ .0002) for the initial alloHCT were associ-
ated with better survival (Table 4). In contrast, age > 41 years
(HR, 1.42; P < .0001), unfavorable cytogenetics (HR, 1.37; P <
.0062), mismatched URD (HR, 1.61; P < .0008), UCB (HR, 1.23;
P< .0078), and presence of active GVHD at relapse (HR,1.25; P
< .0001) were independent predictors of inferior survival.
Relapse or persistent leukemia was the primary cause of
death in 71% of cases. Although relapse was the cause of
death in 80% of patients surviving less than 1 year, only 42%
of longer surviving patients died of leukemia. Infection (4%)
followed by GVHD (3%) and organ failure (3%) were the next
most frequent causes of death and were similar in longer and
shorter survivors.
DISCUSSION
In the 1788 AML patients relapsing after myeloablative or
RIC/NMA alloHCT, we found that survival after post-
transplantation relapse was signiﬁcantly inﬂuenced by timeMultivariate
P Value RR (95% CI) P Value
<.0001 <.0001
1.00
<.0001 .55 (.50-.62) <.0001
<.0001 .39 (.32-.49) <.0001





.02 1.00 (.87-1.15) .10





.02 1.15 (.94-1.41) .18
<.0001 1.37 (1.09-1.71) .01
.06 1.13 (.91-1.39) .27
1.00
.01 .77 (.66-.88) .0002
<.0001 .0007
1.00
.0003 1.61 (1.22-2.13) .0008
.37 1.10 (.89-1.36) .37
<.0001 1.23 (1.06-1.42) .01
.20 .0002
1.00
.07 1.25 (1.13-1.39) <.0001
.95 1.05 (.72-1.52) .80
N. Bejanyan et al. / Biol Blood Marrow Transplant 21 (2015) 454e459458from HCT to relapse, patients’ age, cytogenetic risk group,
donor type, HLA matching, and conditioning intensity.
Although similar to prior reports we observed poor survival
after AML relapse after alloHCT [1,2,5,7,11,19], longer remis-
sion after the initial alloHCT was an independent predictor of
better survival. Patients who remained in remission3 years
after HCT had promising survival even after late relapse. In
contrast, patients whose AML relapsed within 6 months of
alloHCT had dismal survival, as observed in prior reports
[1,5]. We also observed favorable survival after relapse in
those receiving a second HCT with or without chemotherapy
and/or DLI, particularly those achieving CR; this outcome is
also consistent with prior reports [1,5,19].
Other prognostic factors associated with survival after
post-alloHCT relapse were patient age, active GVHD at the
time of relapse, cytogenetic risk group, donor type/HLA
matching, and conditioning intensity. Older patients are
more likely to be unﬁt at the time of relapse and unable to
tolerate further intensive therapy, and they aremore likely to
be managed supportively. The 37% of our patients who were
children were more likely to receive further intensive ther-
apy and survive longer. Similarly, active GVHD at the time of
relapse precludes the use of potentially valuable cell-based
therapy and might increase the risk of infectious complica-
tions. Poor survival was seenwith partially matched URD and
UCB transplants [7]. Without the option of DLI for UCB pa-
tients, the only potential curative option for these patients
remains a second HCT, but this was rarely performed.
Somewhat surprisingly, RIC/NMA conditioning at ﬁrst HCT
was associated with better survival independent of patient
age and time from transplantation to relapse. Previous re-
ports of single-institution studies have made similar obser-
vations [5,7]. We speculate that the lower risks of post-HCT
morbidity after RIC/NMA conditioning may allow these pa-
tients to be better candidates for subsequent intensive
therapy versus those treated with more intensive myeloa-
blative alloHCT. It is also possible that leukemia relapse after
RIC/NMA conditioning may remain more sensitive to
chemotherapy than after myeloablative conditioning and
subsequently contribute to a better clinical outcome.
We had no available data to assess the inﬂuence of tumor
burden at the time of relapse on subsequent response to
therapy and survival. In addition, we were unable to sys-
tematically analyze the impact of each therapeutic approach
on subsequent clinical outcomes because these were inter-
mediate events occurring after relapse and data reporting
was incomplete. Additionally, we were unable to directly
assess the effect of immunosuppression withdrawal on
achievement of remission; however, all previous reports
suggest that this approach alone has minimal, if any, thera-
peutic beneﬁt [7,20].
In conclusion, relapse of AML after alloHCT predicted poor
outcomes. We recommend that patients with longer remis-
sion after initial alloHCT be considered for second HCT or
chemotherapy plus DLI, as this approach was associated with
prolonged survival in our cohort. Patients who relapse early,
are elderly, or have active GVHD at the time of relapse are
unlikely to beneﬁt from intensive therapy and might best
be managed supportively. Beyond compassionate supportive
care, new approaches including prevention strategies [21]
are needed for patients with early relapse after alloHCT.
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